| Mechanisms of action of CD20 antibodies P Boross, JHW Leusen American journal of cancer research 2 (6), 676, 2012 | 343 | 2012 |
| The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via Fcγ receptor–mediated cross-linking MB Overdijk, JH Jansen, M Nederend, JJ Lammerts van Bueren, ... The Journal of Immunology 197 (3), 807-813, 2016 | 295 | 2016 |
| In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling S de Haij, JHM Jansen, P Boross, FJ Beurskens, JE Bakema, DL Bos, ... Cancer research 70 (8), 3209-3217, 2010 | 155 | 2010 |
| The inhibiting Fc receptor for IgG, FcγRIIB, is a modifier of autoimmune susceptibility P Boross, VL Arandhara, J Martin-Ramirez, ML Santiago-Raber, ... The Journal of Immunology 187 (3), 1304-1313, 2011 | 140 | 2011 |
| IgA EGFR antibodies mediate tumour killing in vivo P Boross, S Lohse, M Nederend, JHM Jansen, G van Tetering, M Dechant, ... EMBO molecular medicine 5 (8), 1213-1226, 2013 | 126 | 2013 |
| Regulation of complement and modulation of its activity in monoclonal antibody therapy of cancer S Meyer, JHW Leusen, P Boross MAbs 6 (5), 1133-1144, 2014 | 108 | 2014 |
| Coordinate expression of activating Fcγ receptors I and III and inhibiting Fcγ receptor type II in the determination of joint inflammation and cartilage destruction during … K Nabbe, AB Blom, AEM Holthuysen, P Boross, J Roth, S Verbeek, ... Arthritis & Rheumatism 48 (1), 255-265, 2003 | 86 | 2003 |
| Anti-PEG antibodies compromise the integrity of PEGylated lipid-based nanoparticles via complement ME Senti, CA de Jongh, K Dijkxhoorn, JJF Verhoef, J Szebeni, G Storm, ... Journal of Controlled Release 341, 475-486, 2022 | 85 | 2022 |
| The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden P Boross, JHM Jansen, S de Haij, FJ Beurskens, CE van der Poel, ... haematologica 96 (12), 1822, 2011 | 83 | 2011 |
| The inhibitory receptor FcγRII reduces joint inflammation and destruction in experimental immune complex-mediated arthritides not only by inhibition of FcγRI/III but also by … P van Lent, KC Nabbe, P Boross, AB Blom, J Roth, A Holthuysen, ... The American journal of pathology 163 (5), 1839-1848, 2003 | 81 | 2003 |
| Fcγ receptor IIb strongly regulates Fcγ receptor-facilitated T cell activation by dendritic cells N van Montfoort, PAC t Hoen, SM Mangsbo, MGM Camps, P Boross, ... The Journal of Immunology 189 (1), 92-101, 2012 | 76 | 2012 |
| Staphylococcus aureus Formyl Peptide Receptor–like 1 Inhibitor (FLIPr) and Its Homologue FLIPr-like Are Potent FcγR Antagonists That Inhibit IgG-Mediated Effector Functions AM Stemerding, J Köhl, MK Pandey, A Kuipers, JH Leusen, P Boross, ... The Journal of Immunology 191 (1), 353-362, 2013 | 74 | 2013 |
| Cytokine-induced immune complex binding to the high-affinity IgG receptor, FcγRI, in the presence of monomeric IgG CE Van Der Poel, RA Karssemeijer, P Boross, JA Van Der Linden, ... Blood, The Journal of the American Society of Hematology 116 (24), 5327-5333, 2010 | 73 | 2010 |
| Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via Fc receptor-mediated crosslinking. JHM Jansen, P Boross, MB Overdijk, JJL van Bueren, PWHI Parren, ... Blood, The Journal of the American Society of Hematology 120 (21), 2974-2974, 2012 | 69 | 2012 |
| New insights in Type I and II CD 20 antibody mechanisms‐of‐action with a panel of novel CD 20 antibodies S Meyer, M Evers, JHM Jansen, J Buijs, B Broek, SE Reitsma, P Moerer, ... British Journal of Haematology 180 (6), 808-820, 2018 | 65 | 2018 |
| Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice P Boross, JHM Jansen, A Pastula, CE van der Poel, JHW Leusen Immunology letters 143 (1), 44-52, 2012 | 60 | 2012 |
| Effect of immune serum and role of individual Fcγ receptors on the intracellular distribution and survival of Salmonella enterica serovar Typhimurium in murine … H Uppington, N Menager, P Boross, J Wood, M Sheppard, S Verbeek, ... Immunology 119 (2), 147-158, 2006 | 58 | 2006 |
| Destructive arthritis in the absence of both FcγRI and FcγRIII P Boross, PL van Lent, J Martin-Ramirez, J van der Kaa, MHCM Mulder, ... The Journal of Immunology 180 (7), 5083-5091, 2008 | 56 | 2008 |
| Improved in vivo anti-tumor effects of IgA-Her2 antibodies through half-life extension and serum exposure enhancement by FcRn targeting S Meyer, M Nederend, JHM Jansen, KR Reiding, SR Jacobino, J Meeldijk, ... MAbs 8 (1), 87-98, 2016 | 51 | 2016 |
| A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA GJA Rouwendal, MM van der Lee, S Meyer, KR Reiding, J Schouten, ... MAbs 8 (1), 74-86, 2016 | 47 | 2016 |
